Abstract
BackgroundSubgroup analysis of EMPOWER-Lung 1, a 1:1 randomized, open-label Phase 3 study, showed improvements in overall survival (OS) and progression-free survival with cemiplimab monotherapy (CEMI, n=283) versus platinum-doublet chemotherapy (CHEMO,...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
